CTA
RARE icon

Carillon Tower Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History

Carillon Tower Advisers’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$28M Sell
202,025
-17,220
-8% -$2.04M 0.17% 183
2020
Q3 		$18M Buy
219,245
+17,220
+9% +$1.43M 0.24% 153
2020
Q2 		$15.8M Buy
+202,025
New +$13.4M 0.12% 239

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return

Carillon Tower Advisers's RARE Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Ultragenyx Pharmaceutical (RARE) stake by 7.9% in Q4 2020, selling an estimated $2.04M and leaving 202,025 shares worth $28M. The position accounts for 0.17% of the portfolio, ranked #183.

Carillon Tower Advisers first reported a position in RARE in Q2 2020 and has held it in 3 quarters since. 253 funds tracked by Wall St. Rank hold RARE as of Q4 2020.

  • Carillon Tower Advisers held 202,025 shares of Ultragenyx Pharmaceutical worth $28M as of Q4 2020.
  • Carillon Tower Advisers sold 17,220 Ultragenyx Pharmaceutical shares in Q4 2020, an estimated $2.04M.
  • Ultragenyx Pharmaceutical made up 0.17% of Carillon Tower Advisers's portfolio in Q4 2020, its #183 holding.
  • Carillon Tower Advisers first reported a position in Ultragenyx Pharmaceutical in Q2 2020 and has held it in 3 quarters since.
  • 253 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.